

=> d his

(FILE 'HOME' ENTERED AT 15:46:03 ON 12 JAN 2001)

FILE 'MEDLINE' ENTERED AT 15:46:24 ON 12 JAN 2001

L1 77236 S COLLAGEN
L2 6598 S HEMOSTATIC
L3 416 S L1 AND L2
L4 49758 S FIBRINOGEN OR THROMBIN
L5 121 S L4 AND L3
L6 17017 S DEXTRAN
L7 20 S L6 AND L2
L8 15447 S SEPHADEX
L9 2 S L8 AND L2

FILE 'CA' ENTERED AT 15:59:53 ON 12 JAN 2001

L10 24008 S DEXTRAN
L11 44775 S SEPHADEX
L12 12874 S HEMOSTATIC OR COAGULANT
L13 165 S (L10 OR L11) AND (L12)
L14 21735 S CROSS LINK?
L15 0 S L10 AND L14 AND L12
L16 23924 S EPICHLOROHYDRIN
L17 225 S L10 AND L16
L18 193542 S WOUND OR BLEEDING OR HEMO? OR DRESSING
L19 28 S L17 AND L18

FILE 'WPIDS' ENTERED AT 17:09:10 ON 12 JAN 2001

L20 3673 S DEXTRAN
L21 313239 S POLYMER
L22 112195 S BANDAGE OR WOUND OR HEMOSTATIC
L23 107 S L20 AND L22
L24 108131 S CLOT? OR COAGULATION OR HEMOSTATIC
L25 149 S L20 AND L24
L26 158980 S DRESSING# OR BANDAGE OR COVERING#
L27 6 S L26 AND L25

FILE 'MEDLINE' ENTERED AT 17:14:35 ON 12 JAN 2001

L28 1 S L27

FILE 'CA' ENTERED AT 17:15:39 ON 12 JAN 2001

L29 14 S L28

=> log hold

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	50.96	148.38
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-7.84	-14.00

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 17:23:51 ON 12 JAN 2001

FILE 'MEDLINE' ENTERED AT 15:46:24 ON 12 JAN 2001

L1 77236 S COLLAGEN
L2 6598 S HEMOSTATIC
L3 416 S L1 AND L2
L4 49758 S FIBRINOGEN OR THROMBIN
L5 121 S L4 AND L3
L6 17017 S DEXTRAN
L7 20 S L6 AND L2
L8 15447 S SEPHADEX
L9 2 S L8 AND L2

FILE 'CA' ENTERED AT 15:59:53 ON 12 JAN 2001

L10 24008 S DEXTRAN
L11 44775 S SEPHADEX
L12 12874 S HEMOSTATIC OR COAGULANT
L13 165 S (L10 OR L11) AND (L12)
L14 21735 S CROSS LINK?
L15 0 S L10 AND L14 AND L12
L16 23924 S EPICHLOROHYDRIN
L17 225 S L10 AND L16
L18 193542 S WOUND OR BLEEDING OR HEMO? OR DRESSING
L19 28 S L17 AND L18

=> log hold

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	59.54	69.29
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-6.16	-6.16

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 16:14:55 ON 12 JAN 2001

L5 ANSWER 75 OF 121 MEDLINE
 AN 88228703 MEDLINE
 DN 88228703
 TI Topical **hemostatic** agents for dermatologic surgery [see comments].
 CM Comment in: J Dermatol Surg Oncol 1989 Mar;15(3):342-3
 AU Larson P O
 CS Division of Chemosurgery, University of Wisconsin Hospital/Clinic, Madison 53792..
 SO JOURNAL OF DERMATOLOGIC SURGERY AND ONCOLOGY, (1988 Jun) 14 (6) 623-32. Ref: 61
 Journal code: HZA. ISSN: 0148-0812.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA English
 FS Priority Journals; Cancer Journals
 EM 198809
 AB Topical **hemostatic** agents are very helpful in attaining capillary and small vessel hemostasis in dermatologic surgery. The commonly used topical **hemostatic** agents, including oxidized cellulose, absorbable gelatin, and **thrombin** are reviewed, along with newer agents such as microfibrillar **collagen**, fibrin sealants, and acrylates. Agents best suited for certain situations are recommended.
 CT Check Tags: Human; Support, Non-U.S. Gov't Administration, Topical
 *Hemostasis, Surgical: MT, methods
 *Hemostatics: AD, administration & dosage
 *Skin Diseases: SU, surgery
 CN 0 (Hemostatics)

L5 ANSWER 77 OF 121 MEDLINE
 AN 88186930 MEDLINE
 DN 88186930
 TI An in vitro evaluation of the **hemostatic** activity of topical agents.
 AU Eloy R; Baguet J; Christe G; Rissoan M C; Paul J; Belleville J
 CS Unit 37 INSERM, Bron, France.
 SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH, (1988 Feb) 22 (2) 149-57. Journal code: HJJ. ISSN: 0021-9304.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 198807
 AB An in vitro method has been developed for human non-anticoagulated blood to evaluate the enhancing effect of **hemostatic** agents on both plasmatic and cellular activation of the coagulation cascade. The coagulation time and the sequential generation of fibrinopeptide A (FpA) have been used as parameters. The kinetics of generation of FpA has been modeled and mathematically analyzed using the latency time, the slope of the linear part of the curve, and the time necessary to reach half maximal amplitude of FpA in the tube. A maximal amplitude of FpA in the tube. A

very precise evaluation of the **hemostatic** activity of five
different molecules, four being collagenous in nature, is given.

CT Check Tags: Comparative Study; Human
Analysis of Variance
*Blood Coagulation: DE, drug effects
*Collagen: PD, pharmacology
*Fibrinogen: ME, metabolism
*Fibrinopeptide A: ME, metabolism
*Hemostatics: PD, pharmacology
Kinetics
Mathematics
Models, Biological
Regression Analysis
Whole Blood Coagulation Time

RN 25422-31-5 (Fibrinopeptide A); 9001-32-5 (Fibrinogen);
9007-34-5 (Collagen)

CN 0 (Hemostatics)